Epcoritamab for Relapsed/Refractory EBV+ Post-Transplant Lymphoproliferative Disorder of DLBCL-Type

Area of Science:

• Hematology
• Oncology
• Immunotherapy

Background:

• Relapsed/refractory post-transplant lymphoproliferative disorder (R/R PTLD) following solid-organ transplants (SOT) or hematopoietic stem cell transplants (HSCT) presents a significant clinical challenge with limited treatment options.
• Current treatment paradigms for R/R PTLD lack a standard of care, and affected patients are often excluded from clinical trials, highlighting an unmet medical need.
• Recent advancements in diffuse large b-cell lymphoma (DLBCL) treatments, including CD19 CAR-T cell therapy and CD3xCD20 bispecific antibodies, offer potential therapeutic avenues for PTLD.

Purpose of the Study:

• To report a successful case of R/R PTLD treatment using a CD3xCD20 bispecific antibody.
• To evaluate the tolerability and long-term efficacy of Epcoritamab in a patient with R/R PTLD.

Main Methods:

• A single-center case report detailing the treatment of a patient with R/R PTLD.
• Administration of Epcoritamab, a CD3xCD20 bispecific antibody, as a therapeutic intervention.
• Monitoring of patient response, tolerability, and long-term outcomes.

Main Results:

• The patient with R/R PTLD achieved a successful treatment outcome with Epcoritamab.
• The treatment demonstrated good tolerability, with no significant adverse events reported.
• Long-term response was observed, indicating sustained disease control.

Conclusions:

• CD3xCD20 bispecific antibody therapy, exemplified by Epcoritamab, shows promise as an effective treatment for R/R PTLD.
• Epcoritamab offers a well-tolerated therapeutic option for patients with R/R PTLD, addressing a critical unmet need.
• Further investigation and clinical trials are warranted to establish the role of bispecific antibodies in the management of PTLD.